Clinical trial NCT05598190: A577-nm Pro -Yellow Laser In Treatment of Striae Rubra
Official title: A577-nm Pro -Yellow Laser In Treatment of Striae Rubra
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Striae Rubra
Lead sponsor: Al-Azhar University
Sponsor class: OTHER
First posted: 2022-10-28
Enrollment: 18
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Stretch marks or striae are common skin condition occurring in both genders, but they are more prevalent among women. These are linear dermal scars that are accompanied by epidermal atrophy. They usually occur frequently in numerous physiological and pathological conditions, such as adolescent growth, pregnancy, obesity, Cushing disease, Marfan syndrome, and long-term systemic or topical steroid use. Decreased expression of collagen and fibronectin genes has also been associated with striae.

The pro-yellow laser systems can be used in a wide range of indications such as facial erythema, facial telangiectasia, port wine stain nevus, rosacea, poikilo derma civatte, and Becker's nevus

Some of these indications are clinical lesions in the vascular pattern; some are related to the factors that trigger vascularity, such as vascular endothelial growth factor (VEGF) in etiopathogenesis


Eligibility criteria: Inclusion Criteria:

* .Patients diagnosed with striae rubera. .Age groups: at any age. .Sex : ( females).

  * Co-operative patient

Exclusion Criteria:

* Pregnancy .

  * Patient using drugs exacerbating stria as topical or systemic steroid, and patients using other forms of treatment for stria as topical tretinoin, emollients, glycolic acid peel and laser, because that might affect the result of our study.
  * Stria Alba.
  * Skin infection (viral, bacterial or parasitic).
  * Immunosuppressed patients or with history of malignancy or radiation therapy and chronic debilitating diseases and Cushing syndrome.
  * Hypersensitivity to light and intak of photosensitizing drugs.

Primary outcomes:
measure: dermoscopic change of width of striae rubrae
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Assiut
country: Egypt
facility: AZHAR University Hospital
Study officials:
References:
citation: Dover JS, Rothaus K, Gold MH. Evaluation of safety and patient subjective efficacy of using radiofrequency and pulsed magnetic fields for the treatment of striae (stretch marks). J Clin Aesthet Dermatol. 2014 Sep;7(9):30-3.
citation: Kapicioglu Y, Sarac G, Cenk H. Treatment of erythematotelangiectatic rosacea, facial erythema, and facial telangiectasia with a 577-nm pro-yellow laser: a case series. Lasers Med Sci. 2019 Feb;34(1):93-98. doi: 10.1007/s10103-018-2606-6. Epub 2018 Aug 10.
citation: Mohamed EM, Mohamed Tawfik K, Hassan Ahmad W. Successful treatment of facial vascular skin diseases with a 577-nm pro-yellow laser. J Cosmet Dermatol. 2019 Dec;18(6):1675-1679. doi: 10.1111/jocd.12963. Epub 2019 Apr 29.
citation: Temiz SA, Arazov S, Ataseven A, Dursun R. Treatment of Becker's nevus with 577-nm pro-yellow laser: Could it be a new treatment choice? J Cosmet Dermatol. 2021 Feb;20(2):705-706. doi: 10.1111/jocd.13882. Epub 2020 Dec 14. No abstract available.